90 likes | 240 Views
OBESITY AND SMOKING IN PATIENTS WITH BARRETT’S OESOPHAGUS OR OESOPHAGEAL ADENOCARCINOMA - PRELIMINARY RESLUTS FROM. the. finbar. study. Lesley Anderson BSc (Hons) Research Assistant, NICR. the. finbar. study. The finbar study.
E N D
OBESITY AND SMOKING IN PATIENTS WITH BARRETT’S OESOPHAGUS OR OESOPHAGEAL ADENOCARCINOMA - PRELIMINARY RESLUTS FROM the finbar study Lesley Anderson BSc (Hons) Research Assistant, NICR
the finbar study The finbar study All Ireland case-control study designed to determine possible environmental, lifestyle and genetic risk factors involved in the development of Barrett’s oesophagus and oesophageal adenocarcinoma.
the finbar study Information gathered • Questionnaire: • gastro-oesophageal reflux symptoms • previous medical history • medication usage • Diet • Alcohol • Smoking • Weight • Psychological profile • Anthropometric data - height, weight, waist-hip ratio, leg length • Blood pressure • 30ml blood sample - genetics, vitamin analysis, serological testing
Recruitment to date: Obesity • 193 patients with long segment BO • 234 patients with oesophageal adenocarcinoma • 212 normal controls Increasing rapidly in the UK & Ireland and in the USA. 5 years prior to the interview date: • 34.2% of adenocarcinoma patients • 16.6% of Barrett’s oesophagus patients • 19.8% of normal controls were classified as obese (>30kg/m2)
Body Mass Index (BMI)Odds ratios & 95% Confidence Intervals (CI) 5 YEARS PRIOR TO INTERVIEW BMI(kg/m2) Barrett’s Oesophagus Oesophageal adenocarcinoma <24.3 24.3-26.5 >26.5 1.00 (Reference) 1.06 (95% CI 0.63-1.78) 0.86 (95% CI 0.50-1.49) 1.00 1.19 (95% CI 0.66-2.16) 2.38 (95% CI 1.35-4.17) AGE 21 BMI(kg/m2) Barrett’s Oesophagus Oesophageal adenocarcinoma <24.3 24.3-26.5 >26.5 1.00 (Reference) 0.75 (95% CI 0.44-1.26) 0.88 (95% CI 0.52-1.48) 1.00 1.16 (95% CI 0.65-2.07) 2.58 (95% CI 1.47-4.52)
the finbar study SmokingOdds ratios & 95% Confidence Intervals (CI) 5 YEARS PRIOR TO INTERVIEW Barrett’s Oesophagus Oesophageal adenocarcinoma Smoking Never Ex-smoker Current 1.00 (Reference) 1.15 (95% CI 0.70-1.89) 1.64 (95% CI 0.88-3.03) 1.00 2.23 (95% CI 1.30-3.84) 4.97 (95% CI 2.60-9.49)
the finbar study Sponsors of the finbar study Ulster Cancer Foundation Research & Development Office (Northern Ireland) Health Research Board (Republic of Ireland)
the finbar study STEERING COMMITTEE Dr Liam Murray (PI) Dr Harry Comber Dr Brian Johnston Mr Jim McGuigan Prof John Reynolds Dr Peter Watson CLINICAL PANEL Mr Jim McGuigan Prof Gerry O’Sullivan Prof John Reynolds SCIENTIFIC ADVISORS Prof Chris Wild Prof Janusz Jankowski Dr Ross McManus ASSOCIATE INVESTIGATORS BELFAST Dr Geraldine Cuskelly Dr Ann McGinty Dr Anne Hughes Dr Damien McManus Dr Anna Gavin DUBLIN Prof Dermot Kelleher Dr Ross McManus Dr Lisa Higgins CORK Prof Gerry O’Sullivan LEEDS Prof Chris Wild Dr Laura Hardie LEICESTER Prof Janusz Jankowski RESEARCH TEAM BELFAST Seamus Murphy Lesley Anderson Carol Anderson Martin McAnaespie DUBLIN Majella Gallagher CORK Siobhan Reynolds The Finbarstudy